Reply to Hasford and to Spinola et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32845306 August 2020
We proposed human challenge trials (HCTs) as a possible alternative or complement to conventional phase 3 trials for expedited severe…

Response to Cioffi.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32348499 June 2020
Dr Cioffi rails against our comparison of human challenge studies to organ donation, but the risk of donor death from…

Response to Dawson et al.

Author(s): Eyal N, Lipsitch M, Smith PGJournal: J Infect DisPMID: 32495823 June 2020
Dawson et al raise three concerns about human challenge trials to assess the efficacy of SARS-CoV-2 vaccines. First, that current…